Navigation Links
Reshaping pharmaceutical quality
Date:6/2/2008

The first scientific papers outlining the progress made on the Product Quality Lifecycle Implementation (PQLI) initiative are being published in the June 2008 issue of the Journal of Pharmaceutical Innovation (JPI). Written by experts representing the global pharmaceutical manufacturing industry, these papers present practical scientific and technological approaches to implementing ICH* documents that address pharmaceutical development, quality risk management and pharmaceutical quality systems. The June issue will be published in print and is available free of charge on Springer's electronic information platform SpringerLink at http://www.springerlink.com/content/1939-8042 with the possibility to comment.

The PQLI initiative was launched by the International Society for Pharmaceutical Engineering (ISPE) in June 2007 to help industry find practical technical solutions to the challenges of implementing guidelines put forth by the ICH. The first three task teams formed focused on criticality, design space and control strategy, and how these areas are linked; a Legacy Products Task Team has also been formed as the fourth topical area. PQLI is projected to be at least a five-year initiative that has started with interactive fact-gathering sessions held in the USA and Europe. For background information on the PQLI papers, please see http://springer.com/12247.

The criticality study describes a mechanism for categorizing and delineating criticality for quality attributes, variables, material attributes and process parameters in accordance with a risk-based approach reflective of quality by design (QbD) principles. Design space discussions considered the linkage of the patient experience with product quality. The Control Strategy Team has proposed a model process to enable a clear logic to be used on how a control strategy differentiates between patient and business requirements, as well as showing the linkage from critical quality attributes. The Legacy Products Team has started work and will produce a paper later in 2008 in JPI.

"The task teams are to be congratulated for their technical publications in the Journal of Pharmaceutical Innovation which embrace input from interactive global workshops that included participation from both industry and regulators," said Moheb M. Nasr, Ph.D., Director, Office of New Drug Quality Assessment (CDER, FDA). "These papers, and the PQLI initiative, are important 'next steps' to facilitate the implementation of QbD and to answer the tangible challenges."

Jacques Morenas (AFSSAPS) and current chairman of the Pharmaceutical Inspection Cooperation Scheme (PIC/S) said, "EU regulators are ready to work with ISPE on the future role of the EU Qualified Person, taking into account how critical it is. Work is already in progress as we can see from efforts made in conjunction with the Processed Analytical Technology (PAT) Team at the European Medicines Agency (EMEA) level and we will be happy to continue."


'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
3. Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
6. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
7. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
8. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
9. FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management
10. Research Study Shows That Pharmaceutical Field Sales Reps Productivity Inhibited by Unnecessary Internal Communication
11. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: